The deal with pharmaceutical company Laxisam is one of several agreed by the Russian Direct Investment Fund in recent weeks to supply the vaccine, which is currently being tested in a large-scale trial in Moscow.

It has also made supply deals with Kazakhstan, India, Mexico and two Brazilian states.

The Guardian


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.